Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
4,001 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis.
Suleja A, Bret D, Miszczyk M, Dong W, Zhou X, Laukhtina E, Englinger B, Rajwa P, Karakiewicz PI, Achard V, Szabados B, Compérat E, Rosenberg JE, Zhou P, Shariat SF. · World J Urol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
Maguire WF, Chang E, Mulkey F, Hsu V, Wu H, Truong TM, Kappel D, Kraft J, Yu J, Gao X, Pierce WF, Rahman NA, Fiero MH, Amiri-Kordestani L, de Claro RA, Suzman DL. · Clin Cancer Res · 2026 · cited 0 timesrandomized controlled trial
- Evaluation of Candidate Urinary microRNAs in Upper Tract Urothelial Carcinoma: A Prospective Multicenter Biomarker Study (JCOG1403A1).
Tatarano S, Enokida H, Nishiyama H, Kojima T, Yoshino H, Mitsui T, Ito A, Habuchi T, Kanato K, Kitamura H. · Genes (Basel) · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis.
Yajima S, Okumura G, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, Hirakawa A, Masuda H, Fujii Y. · Crit Rev Oncol Hematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.
Cella L, Fasulo V, Uleri A, Piccolini A, Mallia V, Sormani F, Finocchiaro A, Contieri R, Moretto S, Avolio PP, Saita A, Hurle R, Casale P, Lughezzani G, Buffi NM, Lazzeri M, Paciotti M. · Sci Rep · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Zhang W, Wu H, Wang L, Xu H, Lin T, Tan P, Zhang P, Zheng X. · JAMA Netw Open · 2026 · cited 0 timesOpen accesssystematic review, network meta-analysis
- Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis.
Yajima S, Imasato N, Hashimoto T, Kobayashi S, Ishii G, Masuda H. · Urol Oncol · 2026 · cited 0 timessystematic review, review
- A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).
Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. · ESMO Open · 2026 · cited 0 timesOpen accessclinical trial, phase ii, brief-report
- Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.
D'Souza AA, Groshen SG, Tsao-Wei D, Ruel N, Dorff TB, Lara PN, Twardowski PW, Stadler WM, Tripathi A, Synold TW, Quinn DI, Newman EM. · Curr Probl Cancer · 2026 · cited 0 timesclinical trial, phase ii, comparative study
- Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Sanagawa A, Kato H, Inoue T, Iwamoto T. · Clin Genitourin Cancer · 2026 · cited 0 timesmeta-analysis, systematic review
- Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Nemat S, Gogate J, Li Q, Abdelgawad M, Siefker-Radtke AO. · ESMO Open · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.
Lee CH, Shepherd A, Sathianathen N, Hwang JE, Hwang EC, Kim MH, Narayan V, Jung JH, Dahm P. · Cochrane Database Syst Rev · 2026 · cited 0 timesmeta-analysis, systematic review
- ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025.
Li J, Tang C, Yang L, Song C, Pan H. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.
Zhou Q, Bao G, Liu M, Gong L. · BMC Urol · 2026 · cited 0 timesOpen accessmeta-analysis
- Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
Li Z, Izadmehr S, Hoffman-Censits J, Maughan B, Mayer T, Tan A, Brody R, Xie H, Nie K, Kelly G, Ioannou G, Cabal R, Tuballes K, Guo R, Figueiredo I, Del Valle DM, Mehrazin R, Yu M, Zhao Q, Kim-Schulze S, Sfakianos JP, Gupta S, Hahn NM, Gonzalez-Kozlova E, Gnjatic S, Galsky MD. · Clin Cancer Res · 2026 · cited 0 timesOpen accessclinical trial, phase ii, randomized controlled trial
- First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.
Matsubara N, Saijo K, Shimizu Y, Okano S, Nakano K, Nishio N, Otsuka T, Kuno H, Miura T, Kubota T, Ikezawa H, Umetsu Y, Ito K, Apfel A, Ye Y, Honma Y. · Cancer Sci · 2026 · cited 0 timesOpen accessmulticenter study, clinical trial, phase i
- Incidence and Spectrum of Adverse Events With Enfortumab Vedotin Therapy in Advanced or Metastatic Urothelial Carcinoma: Evidence From a Systematic Review and Meta-Analysis.
Li X, Leng W, Hu W, Gao D, Zhu Z, Lin J, Xu C. · Arch Esp Urol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis
Wang Z, Shao B, Huang D, Ke L. · Front Pharmacol · cited 0 timesOpen accesssystematic-review, review
- A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guérin-Unresponsive Urothelial Carcinoma of the Bladder.
DeCastro GJ, Joffe BI, Stein MN, Abate-Shen C, Miles CH, Gray JM, Anderson CB, Lenis AT, McKiernan JM. · J Urol · 2026 · cited 4 timesclinical trial, phase ii
- ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.
Mirza W, Hussain K, Anwaar A, Shaikh A, Sajid MF, Irfan W, Ali RN. · World J Urol · 2026 · cited 0 timesmeta-analysis, comparative study
- Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.
Menegat ALRS, Menegat BLRS, Braz LDG, Piccoli MVF, Rebelo TG, de Moraes FCA. · Immunotherapy · 2026 · cited 1 timesmeta-analysis, systematic review
- Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis.
Wang Z, Shao B, Huang D, Ke L. · Front Pharmacol · 2026 · cited 0 timessystematic review
- The Prognostic Value of Tumor HER2 Expression in Predicting Oncological Outcomes of Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Alibeiginejad MH, Esmaielpour A, Tsuboi I, Matsukawa A, Yanagisawa T, Mori K, Kardoust Parizi M. · Int J Mol Sci · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.
Mach KE, Kornberg Z, Shkolyar E, Long J, Lee TJ, La V, Yoo I, Rodriguez G, Thong AE, Prado KB, Shah JB, Leppert JT, Skinner EC, Liao JC. · J Clin Invest · 2026 · cited 0 timesOpen accessclinical trial, validation study
- Distal ureterectomy versus radical nephroureterectomy for nonmetastatic distal ureteral urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis of comparative studies.
Mirza W, Hussain K, Khalid M, Ali RN, Moeen-Ud-Din MB, Hadhoud AM. · World J Surg Oncol · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.